Novelix Pharmaceuticals Limited (BOM:536565)

Novelix Pharmaceuticals Ratios and Metrics

Market cap in millions INR. Fiscal year is April - March.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jan 15, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022	Mar 31, 2021
Market Capitalization	987	265	139	73	72	55
Market Cap Growth	1018.47%	90.16%	91.00%	1.24%	31.51%	248.45%
Enterprise Value	973	263	114	47	68	32
Last Close Price	56.06	26.61	17.19	9.00	8.89	6.76
PE Ratio	73.89	313.26	1337.29	-	-	-
PS Ratio	1.16	0.86	3.07	3.80	0.81	0.57
PB Ratio	3.86	1.51	1.89	1.01	0.94	0.74
P/TBV Ratio	3.97	1.51	1.89	1.01	0.97	0.80
P/FCF Ratio	-	-	-	-	-	3.50
P/OCF Ratio	-	-	-	-	4.54	3.44
EV/Sales Ratio	1.15	0.86	2.52	2.46	0.76	0.34
EV/EBITDA Ratio	75.83	160.02	149.01	-	-	-
EV/EBIT Ratio	79.10	208.07	297.10	-	-	-
EV/FCF Ratio	-6.23	-	-	-	-	2.07
Debt / Equity Ratio	-	-	-	-	0.02	-
Asset Turnover	2.02	1.78	0.62	0.24	0.97	0.82
Inventory Turnover	48.72	50.81	10.24	2.12	10.66	11.36
Quick Ratio	1.26	1.96	373.65	60.39	4.98	1.92
Current Ratio	1.53	2.79	407.44	68.83	6.38	3.37
Return on Equity (ROE)	5.49%	0.68%	0.14%	-0.81%	-26.95%	-40.70%
Return on Assets (ROA)	1.83%	0.46%	0.33%	-0.46%	-3.29%	-19.64%
Return on Invested Capital (ROIC)	4.64%	0.84%	0.48%	-1.32%	-9.60%	-46.53%
Return on Capital Employed (ROCE)	4.80%	0.70%	0.50%	-0.80%	-6.20%	-49.50%
Earnings Yield	0.96%	0.32%	0.07%	-0.82%	-28.15%	-68.74%
FCF Yield	-15.82%	-52.09%	-2.47%	-33.05%	-2.94%	28.55%
Buyback Yield / Dilution	-53.46%	9.80%	-28.54%	-	-	-

Source: S&P Global Market Intelligence. Standard template. Financial Sources.